FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1700902612> ?p ?o ?g. }

• W1700902612 endingPage "22347" @default.
• W1700902612 startingPage "22338" @default.
• W1700902612 abstract "// Katherine T. Morris 1 , Eliseo F. Castillo 2 , Anita L. Ray 2 , Lea L. Weston 2 , Robert A. Nofchissey 2 , Joshua A. Hanson 3 , Von G. Samedi 3 , Irina V. Pinchuk 4 , Laurie G. Hudson 5 , Ellen J. Beswick 2 1 Department of Surgery, University of New Mexico, Albuquerque, New Mexico, USA 2 Department of Molecular Genetics and Microbiology, University of New Mexico, Albuquerque, New Mexico, USA 3 Department of Pathology, University of New Mexico, Albuquerque, New Mexico, USA 4 Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA 5 Department of Pharmaceutical Sciences, University of New Mexico, Albuquerque, New Mexico, USA Correspondence to: Ellen J. Beswick, e-mail: ebeswick@salud.unm.edu Keywords: G-CSF, colorectal cancer, NK cells, macrophages, Th1 Received: April 03, 2015      Accepted: May 21, 2015      Published: June 04, 2015 ABSTRACT Granulocyte colony-stimulating factor (G-CSF) is a cytokine that is highly expressed in human and mouse colorectal cancers (CRC). We previously reported that G-CSF stimulated human CRC cell growth and migration, therefore in this study we sought to examine the therapeutic potential of anti-G-CSF treatment for CRC. G-CSF is known to mobilize neutrophils, however its impact on other immune cells has not been well examined. Here, we investigated the effects of therapeutic anti-G-CSF treatment on CRC growth and anti-tumor immune responses. C57BL/6 mice treated with azoxymethane/dextran sodium sulfate (AOM/DSS) to induce neoplasms were administered anti-G-CSF or isotype control antibodies three times a week for three weeks. Animals treated with anti-G-CSF antibodies had a marked decrease in neoplasm number and size compared to the isotype control group. Colon neutrophil and macrophage frequency were unchanged, but the number of macrophages producing IL-10 were decreased while IL-12 producing macrophages were increased. NK cells were substantially increased in colons of anti-G-CSF treated mice, along with IFNγ producing CD4 + and CD8 + T cells. These studies are the first to indicate a crucial role for G-CSF inhibition in promoting protective anti-tumor immunity, and suggest that anti-G-CSF treatment is a potential therapeutic approach for CRC." @default.
• W1700902612 created "2016-06-24" @default.
• W1700902612 creator A5000630127 @default.
• W1700902612 creator A5001222559 @default.
• W1700902612 creator A5006033914 @default.
• W1700902612 creator A5019018814 @default.
• W1700902612 creator A5022402337 @default.
• W1700902612 creator A5033102172 @default.
• W1700902612 creator A5040744117 @default.
• W1700902612 creator A5044838085 @default.
• W1700902612 creator A5051121804 @default.
• W1700902612 creator A5063698784 @default.
• W1700902612 date "2015-06-04" @default.
• W1700902612 modified "2023-10-15" @default.
• W1700902612 title "Anti-G-CSF treatment induces protective tumor immunity in mouse colon cancer by promoting NK cell, macrophage and T cell responses" @default.
• W1700902612 cites W1598929593 @default.
• W1700902612 cites W1976631815 @default.
• W1700902612 cites W1977982136 @default.
• W1700902612 cites W1987520066 @default.
• W1700902612 cites W2002436032 @default.
• W1700902612 cites W2003427825 @default.
• W1700902612 cites W2017791892 @default.
• W1700902612 cites W2019088610 @default.
• W1700902612 cites W2019221616 @default.
• W1700902612 cites W2027752681 @default.
• W1700902612 cites W2028750677 @default.
• W1700902612 cites W2033743084 @default.
• W1700902612 cites W2041413771 @default.
• W1700902612 cites W2042699075 @default.
• W1700902612 cites W2049484673 @default.
• W1700902612 cites W2054367838 @default.
• W1700902612 cites W2056562675 @default.
• W1700902612 cites W2059287796 @default.
• W1700902612 cites W2059310009 @default.
• W1700902612 cites W2059364985 @default.
• W1700902612 cites W2061432532 @default.
• W1700902612 cites W2061476761 @default.
• W1700902612 cites W2063751527 @default.
• W1700902612 cites W2065128783 @default.
• W1700902612 cites W2073932189 @default.
• W1700902612 cites W2074989504 @default.
• W1700902612 cites W2082884465 @default.
• W1700902612 cites W2086468130 @default.
• W1700902612 cites W2088986869 @default.
• W1700902612 cites W2094523807 @default.
• W1700902612 cites W2130078150 @default.
• W1700902612 cites W2140380746 @default.
• W1700902612 cites W2149784020 @default.
• W1700902612 cites W2153178471 @default.
• W1700902612 cites W2153295340 @default.
• W1700902612 cites W2155360682 @default.
• W1700902612 cites W2157884327 @default.
• W1700902612 cites W2157962067 @default.
• W1700902612 cites W2163518962 @default.
• W1700902612 cites W2167363836 @default.
• W1700902612 cites W2274303087 @default.
• W1700902612 cites W26322184 @default.
• W1700902612 cites W78770439 @default.
• W1700902612 doi "https://doi.org/10.18632/oncotarget.4169" @default.
• W1700902612 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4673167" @default.
• W1700902612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26061815" @default.
• W1700902612 hasPublicationYear "2015" @default.
• W1700902612 type Work @default.
• W1700902612 sameAs 1700902612 @default.
• W1700902612 citedByCount "36" @default.
• W1700902612 countsByYear W17009026122016 @default.
• W1700902612 countsByYear W17009026122017 @default.
• W1700902612 countsByYear W17009026122018 @default.
• W1700902612 countsByYear W17009026122019 @default.
• W1700902612 countsByYear W17009026122020 @default.
• W1700902612 countsByYear W17009026122021 @default.
• W1700902612 countsByYear W17009026122022 @default.
• W1700902612 countsByYear W17009026122023 @default.
• W1700902612 crossrefType "journal-article" @default.
• W1700902612 hasAuthorship W1700902612A5000630127 @default.
• W1700902612 hasAuthorship W1700902612A5001222559 @default.
• W1700902612 hasAuthorship W1700902612A5006033914 @default.
• W1700902612 hasAuthorship W1700902612A5019018814 @default.
• W1700902612 hasAuthorship W1700902612A5022402337 @default.
• W1700902612 hasAuthorship W1700902612A5033102172 @default.
• W1700902612 hasAuthorship W1700902612A5040744117 @default.
• W1700902612 hasAuthorship W1700902612A5044838085 @default.
• W1700902612 hasAuthorship W1700902612A5051121804 @default.
• W1700902612 hasAuthorship W1700902612A5063698784 @default.
• W1700902612 hasBestOaLocation W17009026121 @default.
• W1700902612 hasConcept C121608353 @default.
• W1700902612 hasConcept C126322002 @default.
• W1700902612 hasConcept C203014093 @default.
• W1700902612 hasConcept C502942594 @default.
• W1700902612 hasConcept C526805850 @default.
• W1700902612 hasConcept C71924100 @default.
• W1700902612 hasConcept C8891405 @default.
• W1700902612 hasConceptScore W1700902612C121608353 @default.
• W1700902612 hasConceptScore W1700902612C126322002 @default.
• W1700902612 hasConceptScore W1700902612C203014093 @default.
• W1700902612 hasConceptScore W1700902612C502942594 @default.
• W1700902612 hasConceptScore W1700902612C526805850 @default.
• W1700902612 hasConceptScore W1700902612C71924100 @default.

• next